Background. We performed a phase 2 noninferiority trial examining the early fungicidal activity (EFA) of 3 short-course, highdose liposomal amphotericin B (L-AmB) regimens for cryptococcal meningitis (CM) in Tanzania and Botswana.
that increasing L-AmB dosing from the currently recommended 3-4 mg/kg may lead to improved outcomes and that very shortcourse regimens may be as effective as daily therapy [17, 19] . The concept of single-or intermittent-dose L-AmB therapy has been tested in prophylaxis for hematology patients, with single doses of up to 15 mg/kg given without significant toxicities [20] [21] [22] , and is established in treatment of visceral leishmaniasis where single doses of 10 mg/kg are routinely given and have been shown to be efficacious [23] .
The strategy of short-course, high dosing of L-AmB for HIVassociated CM has not been previously tested in a clinical trial.
We performed an open-label phase 2 randomized noninferiority trial to compare alternative short-course L-AmB regimens for the treatment of HIV-associated CM. Our aim was to determine which, if any, of the 3 alternative schedules of intermittent high-dose L-AmB could be adopted for the development of a phase 3 randomized controlled clinical endpoint trial. We measured the effects on early fungicidal activity, which is associated closely with all-cause mortality [9, 24, 25] .
MATERIALS AND METHODS
The trial protocol for the Ambition-cm Trial (Ambisome Induction Optimization for Cryptococcal Meningitis) has previously been published in full [26] . The study was carried out at Princess Marina Hospital (Gaborone, Botswana) and Bugando Medical Centre and Sekou Toure Hospital (Mwanza, Tanzania). The study was approved by the research ethics committees of the London School of Hygiene and Tropical Medicine, the University of Pennsylvania, the Botswana Ministry of Health, and the National Institute of Medical Research Tanzania. The study was conducted in accordance with the principles of International Conference of Harmonisation good clinical practices and was prospectively registered on the International Standard Randomized Controlled Trial Register (ISRCTN 10248064).
Participants and Procedures
Between October 2014 and September 2016, sequential HIVinfected adults aged ≥18 years with a first episode of CM, diagnosed by cerebrospinal fluid (CSF) India ink or cryptococcal antigen (CrAg) lateral flow assay (IMMY, Norman, Oklahoma), were screened for enrollment in the trial. Pregnant or lactating patients, patients with a previous serious reaction to study drugs, or patients on antifungal treatment for >48 hours were excluded. Patients who were both antiretroviral therapy (ART) naive and ART exposed were recruited. Written informed consent was obtained from participants or, in the case of mental obtundation, from a guardian or person with legal responsibility. Patients with mental obtundation were reconsented on recovery.
Patients were block randomized individually to 1 of 4 treatment groups by means of random computer-generated lists with an allocation ratio of 1:1:1:1 and block sizes of 8. Randomization lists were created by an independent statistician who prepared sealed envelopes in advance that were sent to the sites. Trial pharmacists were responsible for randomization at each site. Randomization was stratified by abnormal mental status (Glasgow Coma Scale [GCS] score of 15 or <15) and ART status on admission at each site. The patients and clinical trial team were not blinded. Laboratory staff performing quantitative fungal cultures were blinded to treatment allocation.
The 4 treatment arms were (i) L-AmB (AmBisome, Gilead Sciences) 10 mg/kg on day 1 (single dose); (ii) L-AmB 10 mg/kg on day 1 and 5 mg/kg on day 3 (2 doses); (iii) L-AmB 10 mg/kg on day 1 and 5 mg/kg on days 3 and 7 (3 doses); and (iv) L-AmB 3 mg/kg/day for 14 days (control). L-AmB was given by intravenous infusion over 2 hours. All patients also received 1200 mg/day oral fluconazole (Diflucan [Pfizer] or fluconazole [Medopharm] ) for the first 2 weeks. Unless contraindicated, all patients received 1 L of 0.9% normal saline with 20 mmol of potassium chloride (KCl) prior to L-AmB to minimize nephrotoxicity and were routinely given oral potassium (16 mmol KCl twice daily) and magnesium (11 mmol Mg 2+ once daily) supplementation and daily trimethoprim-sulfamethoxazole prophylaxis. After the 2-week induction phase, patients received fluconazole 800 mg/day until 10 weeks and 200 mg/day thereafter. ART consisting of tenofovir, emtricitabine, and efavirenz was commenced 4-6 weeks after initiation of antifungal therapy in individuals not already on ART.
Evaluations and Outcomes
At baseline patients underwent a lumbar puncture (LP) for opening pressure, cell count and differential, protein, glucose, India ink, CrAg, quantitative fungal culture, and routine bacterial culture. LPs for opening pressure measurements and CSF samples for quantitative fungal culture were repeated on treatment days 3, 7, and 14. Patients with a CSF opening pressure >30 cm H 2 O or symptoms of raised intracranial pressure underwent daily LPs to remove CSF in accordance with guidelines [15] . Quantitative cryptococcal cultures were plated in serial 10-fold dilution and the dilution with the least colonies, but at least 30 colony-forming units (CFUs)/200 μL, was used to calculate CFU/mL quantitative cryptococcal culture results, as previously described [24] . A linear regression of log 10 CFU/mL against time was calculated for each patient. All data points were analyzed except sterile cultures in the second week if these values lessened the slope, as sterility would have been achieved before that day's LP and using the second week's value would therefore underestimate the true slope [9, 24] . All participants had baseline blood tests including full blood count, urea, creatinine, electrolytes, alanine aminotransferase (ALT), HIV test (if status unknown), and CD4 cell count. During the 2-week induction phase, patients underwent alternate-day renal function and electrolyte assessment and twice-weekly monitoring of full blood count and ALT. Clinical and laboratory adverse events (AEs) were graded using the National Institutes of Health Division of AIDS toxicity table [27] . Clinical response was monitored daily for the first 2 weeks or until discharge (whichever was later), then in a follow-up clinic 3, 4, 6, and 10 weeks after starting therapy.
The primary outcome measure was the mean rate of decrease in CSF cryptococcal CFU, also known as early fungicidal activity (EFA) of each L-AmB treatment arm. Secondary outcome measures were mortality at 2 and 10 weeks; proportion of patients in each treatment arm suffering clinical and laboratory-defined grade 3/4 AEs; and median percentage change from baseline in laboratory-defined parameters.
Statistical Analysis
Using a noninferiority design, assuming an EFA of 0.50 log 10 CFU/mL/day with a standard deviation of 0.25 log 10 CFU/ mL/day in the standard daily dosing arm, with a prespecified acceptable Δ of 0.2 log 10 CFU/mL/day, 1-sided α of .025, and 90% power, gave a sample size of 33 patients per arm. The prespecified Δ of 0.2 log 10 CFU/mL/day was selected on the basis of prior evidence showing increased mortality once EFA falls below 0.3 log 10 CFU/mL/day (ie, the projected 0.50 log 10 CFU/ mL/day in the control arm minus prespecified Δ of 0.2 log 10 CFU/mL/day) [26] . A sample size of 40 patients per arm (160 patients in total) was planned to allow for patients who died prior to obtaining EFA measurement. An interim analysis was planned after 80 participants were randomized in the study. The primary analysis was based on the intention-to-treat population. Patients who died before having a repeat LP on day 3 or those with a negative baseline culture could not have an EFA calculated and were therefore not included the EFA analysis, but were analyzed for secondary endpoints. Linear regression models were used, with the mean rate of decrease in log 10 CSF cryptococcal CFU (EFA) being the dependent variable and the treatment groups (using the control group as a comparator) the primary independent variables. The short-course L-AmB groups were compared to the control arm for noninferiority using the prespecified Δ of 0.2 log 10 CFU/mL/day. Statistical significance was defined as P ≤ .05. Following an unadjusted EFA analysis, adjusted analysis was performed including covariates that may determine outcomes (baseline fungal burden, CD4 cell count, abnormal mental status, sex, age, and ART status) giving summary differences with 95% confidence intervals (CIs). Grade 3 and 4 AEs were tabulated by study arm, and the overall numbers of AEs compared using the χ 2 test. The proportion of patients experiencing grade 3 and 4 anaemia, renal impairment, and hypokalemia during 2-week induction treatment was compared across study arms using the χ 2 test.
Mean change in hemoglobin and percentage change in creatinine during 2-week induction therapy were compared across study arms using analysis of variance analysis and χ 2 testing, respectively. Mortality was compared across groups using χ 2 testing. Data were analyzed using Stata version 13 software (StataCorp, College Station, Texas).
RESULTS
The study was stopped on the recommendation of the independent data monitoring committee at the preplanned interim analysis as the primary objective had been achieved, with noninferiority achieved in all 3 study arms at both the predefined 95% confidence level and the stringent 99% confidence level, and no safety concerns with short-course treatment, with the recommendation that the trial proceed onto the clinical endpoint phase 3 trial. At the time of stopping, 134 patients had been screened for the trial. Fifty-four patients were excluded (Figure 1 ), and 80 patients were enrolled and randomized to 1 of the 4 treatment groups: 18 to single dose, 20 to 2 doses, 21 to 3 doses, and 21 to control. One patient was excluded after randomization after it emerged they had been treated for a previous episode of CM; thus 79 patients completed the study, with no loss to follow-up during the initial 2-week induction phase. All participants received the treatment as per the randomization arm. One patient was lost to follow-up between 2 and 10 weeks. Baseline clinical and laboratory characteristics were well balanced between treatment groups (Table 1) . Twenty-five patients (32%) were on ART at presentation with CM, the median baseline CD4 count was 32 cells/µL, and 28% (22) had a GCS score <15.
Primary Outcome
EFA was calculated for 69 patients (17 in the control group, 16 in the single-dose group, 18 in the 2-dose group, and 18 in the 3-dose group). Five patients died prior to follow-up LP and 5 patients had negative baseline cultures precluding EFA calculation. All the short-course, high-dose arms of L-AmB were noninferior in terms of EFA to 14 days of standard-dose L-AmB at the predefined noninferiority margin of 0.2 log 10 CFU/mL/ day ( Figure 2A ). The mean (standard deviation) EFA was -0.41 (0.11) log 10 CFU/mL/day with standard treatment (control), -0.52 (0.35) log 10 CFU/mL/day with single-dose L-AmB, -0.47 (0.29) log 10 CFU/mL/day with 2 doses, and -0.54 (0.44) log 10 CFU/mL/day with 3 doses. The difference in mean EFA between single dose and control was -0.11 (95% CI, -.29 to .07) log 10 CFU/mL/day; between 2 doses and control was -0.05 (95% CI, -.20 to .10) log 10 CFU/mL/day; and between 3 doses and control was -0.13 (95% CI, -.35 to .09) log 10 CFU/mL/day. There was no evidence for any dose-response effect with additional L-AmB doses, suggesting maximal fungicidal activity was achieved with a single 10 mg/kg dose. This remained the case when the analysis was adjusted for factors that have previously been shown to affect EFA (CSF fungal burden and CD4 cell count), abnormal mental status, and also sex, age, and ART status ( Figure 2C ). and 50% (10/20) in the 3-dose arm (P = .09; Table 2 ). Mortality at 10 weeks was associated with abnormal mental status at baseline in univariable analysis (odds ratio, 3.75 [95% CI, 1.3-10.7]), but not with baseline fungal burden, baseline CD4 cell count, or ART status. The mortality difference between the single-dose and control arms was 6.4% (95% CI, -21% to 34%).
Safety
There were no safety concerns with short-course treatment in terms of fungal clearance, and no patients receiving shortcourse L-AmB required additional "rescue" L-AmB therapy. The 3 high-dose short-course L-AmB regimens were all well tolerated. Eighty-eight grade 3 and higher AEs occurred in 47 patients: 45 grade 3 and 43 grade 4/5 AEs, with no significant differences observed between treatment arms (Table 3) . Of these, 49 were clinical, and 39 laboratory AEs. There were 10 grade 3 and 2 grade 4 AEs that were attributed to treatment with L-AmB, all of which were expected L-AmB-related side effects (3 grade 3 hypokalemia, 1 grade 4 hypokalemia, 1 grade 3 hypomagnasemia, 4 grade 3 creatinine rises, 1 grade 3 and 1 grade 4 anemia, 1 grade 4 hyponatremia). Both grade 4 L-AmB related events occurred in the control group. During induction therapy, grade 3 and 4 anemia occurred in 6% (n = 5) and 1% (n = 1) overall, renal impairment in 5% (n = 4) and 1% (n = 1) overall, and hypokalemia in 1% (n = 1) and 1% (n = 1) overall, with no significant differences between treatment arms (Table 2) . Eleven trial participants were readmitted to hospital during the 10-week follow-up period, at a median of 41 (interquartile range, 25-55) days, including 4 in the control arm, 4 in the single-dose arm, none in the 2-dose arm, and 3 in the 3-dose arm. Cryptococcal immune reconstitution inflammatory syndrome (IRIS) was suspected or diagnosed in 5 of the 45 (11%) patients initiating ART, 2 of whom died, with no significant differences between study arms.
DISCUSSION
The use of a single 10 mg/kg dose of L-AmB was noninferior to standard 3 mg/kg daily dosing for 14 days in reducing CSF cryptococcal burden in patients with a first episode of HIVassociated CM. These findings are consistent with previous human and animal studies demonstrating that shorter courses of amphotericin-based treatment may be better tolerated and as effective as conventional 14-day courses [13, 17, [28] [29] [30] .
High dosages of L-AmB were well tolerated, and the safety profile of all L-AmB regimens tested compared favorably to data from prior clinical trials using conventional AmB-d in similar patient populations, both in terms of mortality at 10 weeks and drug-induced toxicities [9, 11] . Overall rates of AEs associated with L-AmB were very low, with just 1 patient (1%) developing grade 4 anemia during induction therapy (in the control arm), compared with 18% of a historic cohort of 368 CM patients receiving AmB-d treatment and an identical prehydration and electrolyte supplementation regimen to that used in the current trial [11] . The median fall in hemoglobin during the first 2 weeks of treatment was 0.9 g/dL, compared with 2.3 g/dL in the Creatinine, %, mean (95% CI) 14 (3-24) 17 (-9 to 43) 13 (-9 to 35) 24 (6-42) -2 (-22 to 18) .29
Abbreviations: AE, adverse event; CFU, colony-forming units; CI, confidence interval; EFA, early fungicidal activity; L-AmB, liposomal amphotericin B. a Individuals who die prior to the day 3 lumbar puncture (LP) or who were culture negative at baseline do not have an EFA value. Overall, 5 patients died prior to follow-up LP (1 control, 1 single dose, 1 two dose, 2 three dose) and 5 patients had negative baseline cultures (3 controls, 1 single dose, 1 two dose). b All 3 study arms were noninferior to control at the predefined noninferiority margin of 0.2 log 10 CFU/mL/day. The respective difference in mean EFA between single dose and control was -0.11 (99% CI, -.35 to .14) log 10 CFU/mL/day; between 2 doses and control was -0.05 (99% CI, -.26 to .16) log 10 CFU/mL/day; and between 3 doses and control was -0.13 (99% CI, -.42 to .17) log 10 CFU/mL/day. Using this more stringent cutoff, all 3 study arms remained noninferior to control at the predefined noninferiority margin of 0.2 log 10 CFU/mL/day.
previous cohort of AmB-d-treated patients [11] , and there was a median increase in creatinine of 14% over the initial 2 weeks, compared to 73% in the AmB-d-treated cohort [11] . There were no grade 4 AEs attributed to high-dose L-AmB during the trial. Rates of recurrence of CM symptoms and IRIS were low, with suspected IRIS events occurring in 11% of individuals initiated on ART during the trial. Based on these phase 2 results, single-dose 10 mg/kg L-AmB is being taken forward to a phase 3 clinical endpoint trial (ISRCTN 72509687). Given the correlation between EFA and clinical outcome [9, 25] , the rapid EFA seen with single 10 mg/ kg doses of L-AmB should result in a clinically efficacious alternative treatment for CM. The 10-week mortality rate of 22% with the single-dose 10 mg/kg L-AmB selected for study in the phase 3 trial, and the overall mortality rate of 29% in the trial, compare favorably with mortality rates of approximately 40% seen in recent large clinical trials of 2-week AmB-d-based treatment [7] [8] [9] . Notably, these mortality rates were in the context of fluconazole as a second antifungal agent. The addition to high dose L-AmB of a more efficacious agent such as flucytosine, which has been proven to be superior to fluconazole in the recent Advancing CM Treatment in Africa (ACTA) trial [30] , may enable a further reduction in mortality rates. The current phase 2 study was not powered to detect a mortality difference, as shown by the wide 95% CIs around the mortality difference, and as expected, no significant difference in mortality between the 4 L-AmB treatment arms was seen. The higher mortality rate in the 3-dose arm was likely due to chance alone, with 40% (n = 4) of the deaths occurring prior to receipt of the third dose of L-AmB.
In conclusion, we have demonstrated that a single 10 mg/kg dose of liposomal amphotericin B given in combination with high-dose fluconazole is noninferior to daily dosed L-AmB at the standard dose of 3 mg/kg plus high-dose fluconazole in terms of rate of fungal clearance in patients with HIV-associated CM. This short-course treatment strategy is now being tested against AmB-d in a clinical endpoint trial. If confirmed to be effective, single high dosages of L-AmB given with an optimized oral antifungal medication backbone would provide a feasible, well-tolerated, and sustainable treatment regimen for HIV-associated CM in resource-limited settings where the safe administration of AmB-d treatment is not possible. Reductions in the need for toxicity monitoring, fewer drug-related AEs, and the potential for shorter periods of hospitalization are likely to mean that a single high-dose L-AmB treatment strategy is cost effective, and a highly favorable alternative to the current standard of care.
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